Patents by Inventor Gregory M. Butchko

Gregory M. Butchko has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Radioimmunotherapy of lymphoma using anti-CD20 antibodies
    Patent number: 6565827
    Abstract: Methods for the treatment of lymphoma by administration of a B cell-specific antibody are described. The invention encompasses providing to a patient both unlabeled antibodies and antibodies labeled with a radioisotope. A principal advantage of the method is that tumor responses can be obtained in a radiometric dose range that does not require hematopoietic stem cell replacement as an adjunct therapy.
    Type: Grant
    Filed: August 7, 2001
    Date of Patent: May 20, 2003
    Assignees: Coulter Pharmaceutical, Inc., The Regents of the University of Michigan
    Inventors: Mark S. Kaminski, Gregory M. Butchko, Stephan D. Glenn, Richard L. Wahl
  • Radioimmunotherapy of lymphoma using anti-CD20 antibodies
    Patent number: 6287537
    Abstract: Methods for the treatment of lymphoma by adminstration of a B cell-specific antibody are described. The invention encompasses providing to a patient both unlabeled antibodies and antibodies labeled with a radioisotope. A principal advantage of the method is that tumor responses can be obtained in a radiometric dose range that does not require hematopoietic stem cell replacement as an adjunct therapy.
    Type: Grant
    Filed: May 29, 1998
    Date of Patent: September 11, 2001
    Assignees: The Regents of the University of Michigan, Coulter Pharmaceutical, Inc.
    Inventors: Mark S. Kaminski, Gregory M. Butchko, Stephan D. Glenn, Richard L. Wahl
  • Radioimmunotherapy of lymphoma using anti-CD20 antibodies
    Patent number: 6090365
    Abstract: Methods for the treatment of lymphoma by administration of a B cell-specific antibody are described. The invention encompasses providing to a patient both unlabeled antibodies and antibodies labeled with a radioisotope. A principal advantage of the method is that tumor responses can be obtained in a radiometric dose range that does not require hematopoietic stem cell replacement as an adjunct therapy.
    Type: Grant
    Filed: November 18, 1997
    Date of Patent: July 18, 2000
    Assignees: Coulter Pharmaceutical, Inc., Regents of the University of Michigan
    Inventors: Mark S. Kaminski, Gregory M. Butchko, Stephan D. Glenn, Richard L. Wahl
  • Radioimmunotherapy of lymphoma using anti-CD20 antibodies
    Patent number: 6015542
    Abstract: Methods for the treatment of lymphoma by administration of a B cell-specific antibody are described. The invention encompasses providing to a patient both unlabeled antibodies and antibodies labeled with a radioisotope. A principal advantage of the method is that tumor responses can be obtained in a radiometric dose range that does not require hematopoietic stem cell replacement as an adjunct therapy also described is a composition useful in the treatment of lymphoma.
    Type: Grant
    Filed: September 10, 1996
    Date of Patent: January 18, 2000
    Assignees: Coulter Pharmaceutical, Inc., The Regents of the University of Michigan
    Inventors: Mark S. Kaminski, Gregory M. Butchko, Stephan D. Glenn, Richard L. Wahl
  • Radioimmunotherapy of lymphoma using anti-CD20 antibodies
    Patent number: 5843398
    Abstract: Methods for the treatment of lymphoma by administration of a B cell-specific antibody are described. The invention encompasses providing to a patient both unlabeled antibodies and antibodies labeled with a radioisotope. A principal advantage of the method is that tumor responses can be obtained in a radiometric dose range that does not require hematopoietic stem cell replacement as an adjunct therapy.
    Type: Grant
    Filed: April 26, 1996
    Date of Patent: December 1, 1998
    Assignees: Coulter Pharmaceutical, Inc., Regents of the University of Michigan
    Inventors: Mark S. Kaminski, Gregory M. Butchko, Stephan D. Glenn, Richard L. Wahl
  • Radioimmunotherapy of lymphoma using anti-CD20
    Patent number: 5595721
    Abstract: Methods for the treatment of lymphoma by adminstration of a B cell-specific antibody are described. The invention encompasses providing to a patient both unlabeled antibodies and antibodies labeled with a radioisotope. A principal advantage of the method is that tumor responses can be obtained in a radiometric dose range that does not require hematopoietic stem cell replacement as an adjunct therapy.
    Type: Grant
    Filed: September 16, 1993
    Date of Patent: January 21, 1997
    Assignee: Coulter Pharmaceutical, Inc.
    Inventors: Mark S. Kaminski, Gregory M. Butchko, Stephan D. Glenn, Richard L. Wahl